These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27415449)

  • 21. Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.
    Naggie S; Hicks C
    J Antimicrob Chemother; 2010 Jun; 65(6):1094-9. PubMed ID: 20418273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients.
    Burgos J; Crespo M; Falcó V; Curran A; Navarro J; Imaz A; Domingo P; Podzamczer D; Mateo MG; Villar S; Van den Eynde E; Ribera E; Pahissa A
    J Antimicrob Chemother; 2012 Oct; 67(10):2479-86. PubMed ID: 22729925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary pharmacokinetic data on ABT-378 encouraging.
    AIDS Patient Care STDS; 1998 Feb; 12(2):146. PubMed ID: 11361913
    [No Abstract]   [Full Text] [Related]  

  • 24. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
    Zhang Z; Hamatake R; Hong Z
    Antivir Chem Chemother; 2004 May; 15(3):121-34. PubMed ID: 15266894
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New drugs for old.
    Winston A; Stebbing J
    J HIV Ther; 2005 Mar; 10(1):11-6. PubMed ID: 15951729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients.
    Turner D; Schapiro JM; Brenner BG; Wainberg MA
    Antivir Ther; 2004 Jun; 9(3):301-14. PubMed ID: 15259893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Place of protease inhibitors in antiretroviral treatment.
    Tenore SB; Ferreira PR
    Braz J Infect Dis; 2009 Oct; 13(5):371-4. PubMed ID: 20428639
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
    Lima VD; Gill VS; Yip B; Hogg RS; Montaner JS; Harrigan PR
    J Infect Dis; 2008 Jul; 198(1):51-8. PubMed ID: 18498238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 protease inhibitors in development.
    Rusconi S; La Seta Catamancio S
    Expert Opin Investig Drugs; 2002 Mar; 11(3):387-95. PubMed ID: 11866667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening and selecting for optimized antiretroviral drugs: rising to the challenge of drug resistance.
    de Béthune MP; Hertogs K
    Curr Med Res Opin; 2006 Dec; 22(12):2603-12. PubMed ID: 17166342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea.
    Choi JY; Kwon OK; Choi BS; Kee MK; Park M; Kim SS
    J Clin Virol; 2014 Jun; 60(2):154-60. PubMed ID: 24680255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
    Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging HIV-1 resistance to tipranavir and darunavir in patients with virological failure to first-generation protease inhibitors in Taiwan.
    Hsieh SM; Chang SY; Hung CC; Sheng WH; Chen MY; Chang SC
    Int J STD AIDS; 2011 Nov; 22(11):617-20. PubMed ID: 22096044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen.
    Burgos J; Crespo M; Falcó V; Curran A; Imaz A; Domingo P; Podzamczer D; Mateo MG; Van den Eynde E; Villar S; Ribera E
    J Antimicrob Chemother; 2012 Jun; 67(6):1453-8. PubMed ID: 22378681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.
    van Lunzen J; Liess H; Arastéh K; Walli R; Daut B; Schürmann D
    HIV Med; 2007 May; 8(4):220-5. PubMed ID: 17461849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy.
    de la Rosa R; Ruíz-Mateos E; Rubio A; Abad MA; Vallejo A; Rivero L; Genebat M; Sánchez-Quijano A; Lissen E; Leal M
    J Antimicrob Chemother; 2004 Jan; 53(1):95-101. PubMed ID: 14657091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease.
    Adekale MA; Cane PA; McCrae MA
    J Med Virol; 2005 Feb; 75(2):195-201. PubMed ID: 15602725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.
    Bucher HC; Young J; Battegay M
    J Antimicrob Chemother; 2004 Aug; 54(2):303-5. PubMed ID: 15269200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.